^
Association details:
| Biomarker: | LMNA-NTRK1 fusion |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Zykadia (ceritinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 5280: Kinase fusions drive endocrine resistance in estrogen receptor-positive breast cancer
Published date:
05/15/2020
Excerpt:
Similarly, expression of the EML4-ALK fusion also activated growth factor signaling pathways and caused resistance to estrogen depletion and induced sensitivity to the ALK inhibitor, Ceritinib
DOI:
10.1158/1538-7445.AM2020-5280
